Similarities and Differences of Epigenetic Mechanisms in Lupus and Sjögren’s Syndrome

Le Dantec C1, Charras A1, Wesley H Brooks2 and Yves Renaudineau1,2,3*

1Immunotherapy Graft Oncology, Innovative Medicines Initiative PRECISESADS, Réseau épidémiétique et réseau canaux ioniques du Cancéropole Grand Ouest, European University of Brittany, Brest, France
2Department of Chemistry, University of South Florida, Tampa, FL, USA
3Laboratory of Immunology and Immunotherapy, CHU Morvan, Brest, France

Corresponding author: Yves Renaudineau, Laboratory of Immunology and Immunotherapy, Brest University Medical School Hospital, BP824, F29609, Brest, France, Tel: +332 98 22 33 84; E-mail: yves.renaudineau@univ-brest.fr

Received date: October 03, 2015; Accepted date: October 06, 2015; Published date: October 13, 2015

Copyright: © 2015 Dantec LC et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome are two systemic autoimmune diseases, which are believed to develop when genetically predisposed individuals undergo epigenetic modifications in response to environmental factors. Recent advances in the understanding of the pathophysiology of these two diseases suggest a multi-step process involving environmental factors leading to distinct cell specific deregulation of the epigenetic machinery, and the effect is reinforced in those patients with risk variants mapping to epigenetically-controlled immune regulators. Finally, it was observed that the PKC-delta/Erk/DNMT1 pathway was altered in both diseases and the effects could be reversed thus providing arguments to suggest that therapeutic strategies targeting this pathway would be effective in both diseases.

Keywords: Systemic lupus erythematosus; Sjögren’s syndrome; Epigenetics; DNA methylation; Histone acetylation; Endogenous retrovirus

Abbreviations

HERV: Human Endogenous Retroviruses; MSG: Minor Salivary Glands

Introduction

Recent advances in our comprehension of the pathophysiology of Autoimmune diseases (AID) strongly suggest a multi-step process that involves environmental factors (e.g. viruses, tobacco, drugs), followed by deregulation of the epigenetic machinery (e.g. DNA demethylation, histone modifications), which in turn specifically affects the immune system and/or the target organs and, last but not least, this process is amplified in the case of genetic mutations [1,2]. As a consequence, autoreactive lymphocytes and autoantibodies (Abs) are produced leading to development of the disease [3]. At the crossroads of environmental and genetic factors, epigenetic processes are deregulated and, in order to highlight important similarities and differences between AID, we have selected systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) as models (Table 1).

Environmental factors

Several lines of evidence strongly support a critical and pathogenic role for environmental factors and subsequent epigenetic deregulation in SLE and pSS development. Such assertion is based on the determination of the disease concordance rates (CR) for monozygotic twins (MZ) revealing a CR of 24-57% for SLE and a CR of 15-25% for pSS, thus supporting an intermediate scenario in which genetics and environmental factors are both involved [1]. Geoepidemiology Analysis has given results that highlight differences between the two diseases since the highest rate of pSS is reported in northern countries while the worldwide distribution of SLE is more homogeneous [4]. Sunlight exposure, smoking, and industrial pollution were associated with SLE, while viruses and psychological stress are reported as contributing factors in pSS [5]. Direct evidence has been provided that UV light, cigarette smoking, and chemicals can induce important epigenetic changes. Regarding drug-induced AID, hydralazine and procainamide, two drugs known to interfere with DNA methylation are well known to induce SLE and SS in both humans and mice. As a whole, these observations strongly suggest a key role-played by DNA methylation and DNA demethylation inducers in the development of these two diseases [6,7].

Retrotransposons

Another argument to consider, with regards to epigenetic deregulation in AID, is to detect abnormal levels of retrotransposons and, among these, human endogenous retroviruses (HERV) [8]. Inserted within the human genome (8%), HERVs are controlled at the epigenetic level by DNA methylation and, when such control is impaired, they can affect the human genome in different ways. One example is related to the human T cell leukaemia related endogenous retrovirus (HRES-1) that is inserted in the long arm of chromosome 1 at position 1q42. DNA methylation controls HRES-1 expression [9], and when expressed, HRES-1 produces a p38gag protein that can induce the development of Abs as observed in 29% of patients with SLE, and 10% of patients with pSS in contrast to 1.5% in healthy donors [10]. An association between SLE and HRES-1 polymorphisms has been described [11]. In minor salivary glands from pSS patients, several HERV-E elements were reported including the SLE T cell provirus HERV-E 4.1 [12]. Another example is HERV-CD5 that is integrated into chromosome 11 upstream of the host cd5 gene exon 1 and downstream of the cd6 gene [13]. This integration occurred just prior to the divergence of hominoids from old world monkeys 25 million years ago [14]. In SLE B cells, defective DNA methylation at HERV-CD5 promoter introduces an alternative promoter for the cd5 gene, and enables transcription of a fusion transcript with the consequence of an intracellular variant of CD5 [15,16], which could, in turn, promote B cell autoreactivity [17,18].
Table 1: Similarities and differences influencing epigenetic factors in systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS).

| Environmental factors | SLE                                                                 | pSS                                                                 |
|-----------------------|---------------------------------------------------------------------|----------------------------------------------------------------------|
| Drugs (procainamide, isoniazide) | Drugs (procainamide, isoniazide)                                    |                                                                      |
| UV lights, smoking    |                                                                      | Virus, stress                                                        |
| Monzygotic twins      | 24-57% concordance rate                                             | 15-25% concordance rate                                              |
| Retrotransposons      | HRES-1 (T and B cells)                                              | HERV-E 4.1 (T cells)                                                 |
|                       | HERV-E CD5 (B cells)                                                | HERV-E 4.1 (minor salivary glands)                                   |
| DNA methylation       | ↓PKC delta-Erk                                                      | ↓PKC delta-Erk                                                       |
|                       | ↓DNMT1, DNMT3a                                                     | ↓DNMT1                                                               |
|                       | ↑Gadd 45 alpha, MBD4                                               | ↑Gadd 45 alpha                                                       |
| Histone modifications | ↑H3-H4 hypoacetylation                                             | unknown                                                              |
|                       | ↑H3k9 trimethylation                                               | unknown                                                              |
| Genetic risk variants | Long range regulatory sequences                                    | Long range regulatory sequences                                      |
|                       | B cells>T cells                                                    | B cells>monocytes                                                    |
| Reversibility         | Anti-CD20 (B cells)                                                | Anti-IL-6R (epithelial cells)                                        |

Genetics

Upto forty non-HLA genetic associations were characterized in SLE and pSS, and the list is growing with development of genome wide association studies (GWAS) and next-generation sequencing (NGS) technologies which contribute to the characterization of rare single nucleotide polymorphisms (SNPs), new copy number variations (CNV) and microsatellites [23]. The development of the ENCODE (Encyclopedia of DNA elements) and roadmap Epigenomic programs were decisive for our comprehension of the associated causal genetic risk-factors revealing that they are present predominantly within cell-specific long range gene-regulatory sequences which are located outside promoters, protein coding regions, splice junctions, and 3’ UTRs [24]. Histone acetylation is effective to control long-range regulatory sequences by controlling transcription factor binding and in turn transcription. However, such control may be altered in the case of genetic risk variants and such effect would predominantly affect B cells in both SLE and pSS [23], while it is T cells that are affected in nearly all AID [1].

Reversibility and cytokines

The anti-CD20 monoclonal antibody (mAb) B-cell-depleting agent rituximab is effective in both SLE and pSS [25-27] and targeting cytokines such as BAFF and IL-6 is also effective in management of SLE [28]. Part of this activity may be attributed to the powerful influence of the biotherapies on the epigenetic machinery. In pSS, treating patients with anti-CD20 mAb therapy restores global DNA methylation in SGEC [21], and the utilization of the anti-IL6 receptor mAb itolizumab in SLE B cells repairs the defective Erk/DNMT1 pathway and DNA methylation [16,29].
Conclusion

The arguments presented here indicate that epigenetic changes (DNA demethylation, histone modifications) confer a risk for SLE and pSS suggesting a strong argument for epigenetic causality in genetically predisposed individuals (Figure 1). Another important point is related to the cellular specificity, which concerns mainly lymphocytes in the case of SLE and epithelial cells in the case of pSS. However, it was also observed that the process was reversible, and that both diseases could be induced by DNA demethylating drugs and are related to a defective PKC-delta/Erk/DNMT1 pathway. As a consequence it can be postulated that drugs controlling this pathway would undoubtedly have benefits for SLE and pSS prevention and treatment [30,31].

Acknowledgements

This work was supported by the "Région Bretagne", the "Association Française Gougerot-Sjögren et des Syndromes Secs", and by the "Institut Français pour la Recherche Odontologique". We are also grateful to Simone Forest and Geneviève Michel for their help in typing the paper. The research leading to these results received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n°115565, resources of which are composed of financial contributions from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in-kind contribution.

References

1. Farh K, Marson A, Zhu J, Kleinewietfeld M, Housley WJ, et al. (2015) Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518: 337-343.
2. Le Dantec C, Gazeau P, Mukherjee S, Brooks WH, Renaudineau Y (2015). How the environment influences epigenetics, DNA methylation, and autoimmune diseases.
3. Thabet Y, Cañas F, Ghedira I, Youinou P, Mageed RA, et al. (2012) Altered patterns of epigenetic changes in systemic lupus erythematosus and auto-antibody production: is there a link? J Autoimmun 39: 154-160.
4. Shapiro Y, Agmon-Levin N, Shoefield Y (2010) Geoepidemiology of autoimmune rheumatic diseases. Nat Rev Rheumatol 6: 468-476.
5. Mavragani CP, Moutsopoulos HM (2010) The geoepidemiology of Sjögren’s syndrome. Autoimmun Rev 9: 305-310.
6. Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y (2010) Epigenetics and autoimmunity. J Autoimmun 34: 207-219.
7. Konsta OD, Le Dantec C, Brooks WH, Renaudineau Y (2015) Genetics and Epigenetics of Autoimmune Diseases. eLS. John Wiley & Sons Ltd, Chichester.
8. Richardson BC, Patel DR (2014) Epigenetics in 2013 DNA methylation and miRNA: key roles in systemic autoimmunity. Nat Rev Rheumatol 10: 72-74.
9. Gorelik G, Savalh AH, Patel D, Johnson K, Richardson B (2015) T cell PKCδ kinase inactivation induces lupus-like autoimmunity in mice. Clin Immunol 158: 193-203.
10. Thabet Y, Le Dantec C, Ghedira I, Devauchelle V, Cornece D, et al. (2013) Epigenetic dysregulation in salivary glands from patients with primary Sjögren’s syndrome may be ascribed to infiltrating B cells. J Autoimmun 41: 171-181.
11. Lu Q, Renaudineau Y, Cha S, Ilei G, Brooks WH, et al. (2010) Epigenetics in autoimmune disorders: highlights of the 10th Sjögren’s syndrome symposium. Autoimmun Rev 9: 627-630.
12. Konsta OD, Le Dantec C, Brooks WH, Renaudineau Y (2015) Genetics and Epigenetics of Autoimmune Diseases. eLS. 1-9.
13. Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, et al. (2015) integrative analysis of 111 reference human epigenomes. Nature 518: 317-330.
14. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, et al. (2007) Improvement of Sjögren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 57: 310-317.
15. Devauchelle PV, Cagnard N, Pers JO, Youinou P, Saraux A, et al. (2010) Gene expression profile in the salivary glands of primary Sjögren’s syndrome patients before and after treatment with rituximab. Arthritis Rheum 62: 2262-2271.
16. Seret G, Le Meur Y, Renaudineau Y, Youinou P (2012) Mesangial cell-specific antibodies are central to the pathogenesis of lupus nephritis. Clin Dev Immunol 2012: 579670.
17. Youinou P, Taher TE, Pers JO, Mageed RA, Renaudineau Y (2009) B lymphocyte cytokines and rheumatic autoimmune disease. Arthritis Rheum 60: 1873-1880.
18. Renaudineau Y, Garaud S, Le Dantec C, Alonso-Ramirez R, Daridon C, et al. (2010) Autoreactive B cells and epigenetics. Clin Rev Allergy Immunol 39: 85-94.
19. Brooks WH, Renaudineau Y (2015) Epigenetics and autoimmunity diseases: the X chromosome-nucleolus nexus. Front Genet 6: 22.
20. Le Dantec C, Chevailler A and Renaudineau Y (2015) Epigénétique et médecine prédictive. Revue Francophone des Laboratoires 473: 71-75.